Mesothelin-ADC - Molecular Diagnostics for Cancer Drug ...
Mesothelin-ADC - Molecular Diagnostics for Cancer Drug ...
Mesothelin-ADC - Molecular Diagnostics for Cancer Drug ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>Mesothelin</strong> expression is unchanged during progression<br />
Score: 0 1 2 3<br />
Case 14 0 / 0% Case 55 10 / 10%<br />
Case 56 80 / 40% Case 38 300 / 100%<br />
<strong>Mesothelin</strong> IHC on matched samples: primary ovarian cancer vs. relapse,<br />
111002_29<br />
Primary<br />
Score 1<br />
Relapse<br />
Score 1<br />
8%<br />
8% 6% same<br />
58%<br />
20%<br />
same<br />
raise<br />
raise (0 becomes 1 or 2)<br />
mild increase<br />
mild increase mild (1 decrease becomes 2)<br />
loss<br />
mild decrease (2 becomes 1)<br />
loss (2 or 1 becomes 0)<br />
58% n=50<br />
<strong>Mesothelin</strong> expression remains stable<br />
during ovarian cancer progression<br />
Archived tumor samples can be used<br />
to select ovarian cancer patients <strong>for</strong><br />
mesothelin-<strong>ADC</strong> therapy.<br />
All staining per<strong>for</strong>med on FFPE tissue with MB-G10 antibody, scoring by Dept. of Pathology, Charité<br />
6 • <strong>Mesothelin</strong> <strong>ADC</strong> • Boston, June 2012 • David Henderson
Change language